Skylar Jeremias

The FDA recently approved Yesintek for treating psoriasis, psoriatic arthritis, and IBD, with a 2025 launch expected.

Regional disparities were highlighted in a study of inpatient dermatology encounters, locations, and providers from 2013 to 2019.

Researchers have developed a clinical decision support model using machine learning to assist health care providers in predicting diagnoses of hidradenitis suppurativa.

Factors such as ultraviolet radiation, rising temperature, and air pollution may all play a role in the increasing incidence of skin cancers.

Authors of a recent review concluded that combining various therapies holds promise in the treatment of acne scarring.

A study revealed that patients with actinic keratosis reported feeling more pain during red light PDT compared to simulated daylight PDT.

A study demonstrated the favorable efficacy and safety profiles of secukinumab in patients with severe HS for up to 52 weeks.

The biosimilar landscape experienced significant activity, marked by fresh data from conferences, novel findings regarding adalimumab biosimilars, and more.

A recent study linked alopecia areata and the presence of cochlear dysfunction in some patients.

Depression, functional impairment, and worsened quality of life are related in patients with psoriatic disease, according to a recent study.

A phase 3 study conducted by Amgen found that the company’s ustekinumab biosimilar was as safe and efficacious as the reference product (Stelara) in patients with moderate to severe plaque psoriasis.

Given the high prevalence of Kawasaki disease during the pandemic, Japanese investigators determined that droplet or contact transmission of pathogens is likely not a major route causing the development of the disease.